Mind Medicine Net Worth
Mind Medicine Net Worth Breakdown | MNMD |
Mind Medicine Net Worth Analysis
Mind Medicine's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Mind Medicine's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Mind Medicine's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Mind Medicine's net worth analysis. One common approach is to calculate Mind Medicine's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Mind Medicine's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Mind Medicine's net worth. This approach calculates the present value of Mind Medicine's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Mind Medicine's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Mind Medicine's net worth. This involves comparing Mind Medicine's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Mind Medicine's net worth relative to its peers.
Enterprise Value |
|
To determine if Mind Medicine is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mind Medicine's net worth research are outlined below:
| Mind Medicine generated a negative expected return over the last 90 days | |
| Mind Medicine has high historical volatility and very poor performance | |
| Net Loss for the year was (108.68 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Mind Medicine currently holds about 105.74 M in cash with (79.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.71. | |
| Mind Medicine has a frail financial position based on the latest SEC disclosures | |
| Roughly 56.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Liao Carrie of 50000 shares of Mind Medicine subject to Rule 16b-3 |
Mind Medicine Quarterly Good Will |
|
Mind Medicine uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mind Medicine. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mind Medicine's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Mind Medicine Target Price Consensus
Mind target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Mind Medicine's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 4 | Strong Buy |
Most Mind analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Mind stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Mind Medicine, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationMind Medicine Target Price Projection
Mind Medicine's current and average target prices are 6.47 and 8.00, respectively. The current price of Mind Medicine is the price at which Mind Medicine is currently trading. On the other hand, Mind Medicine's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Mind Medicine Market Quote on 18th of March 2025
Target Price
Analyst Consensus On Mind Medicine Target Price
Know Mind Medicine's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Mind Medicine is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mind Medicine backward and forwards among themselves. Mind Medicine's institutional investor refers to the entity that pools money to purchase Mind Medicine's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Woodline Partners Lp | 2024-12-31 | 1 M | Tri Locum Partners Lp | 2024-12-31 | 820.8 K | Northern Trust Corp | 2024-12-31 | 684.8 K | Charles Schwab Investment Management Inc | 2024-12-31 | 593.4 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 496.7 K | Ally Bridge Group (ny) Llc | 2024-12-31 | 330.3 K | Goldman Sachs Group Inc | 2024-12-31 | 296.8 K | Nuveen Asset Management, Llc | 2024-12-31 | 286.3 K | Bank Of America Corp | 2024-12-31 | 272.9 K | Blackrock Inc | 2024-12-31 | 6.1 M | Commodore Capital Lp | 4.3 M |
Follow Mind Medicine's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 478.59 M.Market Cap |
|
Project Mind Medicine's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.39) | (0.40) | |
| Return On Capital Employed | (0.39) | (0.41) | |
| Return On Assets | (0.36) | (0.38) | |
| Return On Equity | (0.45) | (0.47) |
When accessing Mind Medicine's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Mind Medicine's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mind Medicine's profitability and make more informed investment decisions.
Please note, the presentation of Mind Medicine's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mind Medicine's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Mind Medicine's management manipulating its earnings.
Evaluate Mind Medicine's management efficiency
Mind Medicine has return on total asset (ROA) of (0.3044) % which means that it has lost $0.3044 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6801) %, meaning that it created substantial loss on money invested by shareholders. Mind Medicine's management efficiency ratios could be used to measure how well Mind Medicine manages its routine affairs as well as how well it operates its assets and liabilities. As of March 18, 2025, Return On Tangible Assets is expected to decline to -0.4. In addition to that, Return On Capital Employed is expected to decline to -0.41. At present, Mind Medicine's Tangible Asset Value is projected to increase significantly based on the last few years of reporting.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.43 | 6.53 | |
| Net Current Asset Value | 171.4 K | 147.7 K | |
| Tangible Asset Value | 3.2 M | 3.3 M | |
| Tangible Book Value Per Share | 3.14 | 6.26 | |
| Enterprise Value Over EBITDA | (2.30) | (2.41) | |
| Price Book Value Ratio | 2.03 | 1.79 | |
| Enterprise Value Multiple | (2.30) | (2.41) | |
| Price Fair Value | 2.03 | 1.79 | |
| Enterprise Value | 238.5 M | 250.4 M |
Mind Medicine has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mind Medicine insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mind Medicine's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mind Medicine insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mind Medicine Corporate Filings
F4 | 13th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 6th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 5th of February 2025 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Mind Medicine Earnings Estimation Breakdown
The calculation of Mind Medicine's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Mind Medicine is estimated to be -0.53 with the future projection ranging from a low of -0.39 to a high of -0.35. Please be aware that this consensus of annual earnings estimates for Mind Medicine is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.39 Lowest | Expected EPS | -0.35 Highest |
Mind Medicine Earnings Projection Consensus
Suppose the current estimates of Mind Medicine's value are higher than the current market price of the Mind Medicine stock. In this case, investors may conclude that Mind Medicine is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Mind Medicine's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 11 | 72.99% | -0.41 | -0.53 | -1.54 |
Mind Medicine Earnings per Share Projection vs Actual
Actual Earning per Share of Mind Medicine refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Mind Medicine predict the company's earnings will be in the future. The higher the earnings per share of Mind Medicine, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Mind Medicine Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Mind Medicine, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Mind Medicine should always be considered in relation to other companies to make a more educated investment decision.Mind Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Mind Medicine's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-26 | 2024-12-31 | -0.2786 | -0.41 | -0.1314 | 47 | ||
2024-11-07 | 2024-09-30 | -0.28 | -0.27 | 0.01 | 3 | ||
2024-08-13 | 2024-06-30 | -0.33 | -0.26 | 0.07 | 21 | ||
2024-05-08 | 2024-03-31 | -0.53 | -1.14 | -0.61 | 115 | ||
2024-02-28 | 2023-12-31 | -0.46 | -0.59 | -0.13 | 28 | ||
2023-11-02 | 2023-09-30 | -0.67 | -0.45 | 0.22 | 32 | ||
2023-08-03 | 2023-06-30 | -0.54 | -0.76 | -0.22 | 40 | ||
2023-05-04 | 2023-03-31 | -0.42 | -0.52 | -0.1 | 23 | ||
2023-03-09 | 2022-12-31 | -0.5 | -0.16 | 0.34 | 68 | ||
2022-11-10 | 2022-09-30 | -0.6 | -0.56 | 0.04 | 6 | ||
2022-08-11 | 2022-06-30 | -0.75 | -0.6 | 0.15 | 20 | ||
2022-05-16 | 2022-03-31 | -0.75 | -0.6 | 0.15 | 20 | ||
2022-03-28 | 2021-12-31 | -0.7 | -0.75 | -0.05 | 7 | ||
2021-11-12 | 2021-09-30 | -0.52 | -0.9 | -0.38 | 73 | ||
2021-08-12 | 2021-06-30 | -0.6 | -1.35 | -0.75 | 125 | ||
2021-05-14 | 2021-03-31 | -0.23 | -0.04 | 0.19 | 82 | ||
2021-03-30 | 2020-12-31 | -0.3 | -0.15 | 0.15 | 50 | ||
2020-11-13 | 2020-09-30 | -0.45 | -0.45 | 0.0 | 0 | ||
2020-08-13 | 2020-06-30 | 0 | -0.03 | -0.03 | 0 | ||
2020-05-14 | 2020-03-31 | 0 | -0.03 | -0.03 | 0 |
Mind Medicine Corporate Management
| MD MA | Chief Officer | Profile | |
| Schond MBA | Chief Officer | Profile | |
| Maxim CFA | Vice Communications | Profile | |
| Wong JD | Chief Sec | Profile | |
| Gregg Pratt | Chief Officer | Profile | |
| MD MBA | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mind Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Mind Stock refer to our How to Trade Mind Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mind Medicine. If investors know Mind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mind Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mind Medicine is measured differently than its book value, which is the value of Mind that is recorded on the company's balance sheet. Investors also form their own opinion of Mind Medicine's value that differs from its market value or its book value, called intrinsic value, which is Mind Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mind Medicine's market value can be influenced by many factors that don't directly affect Mind Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mind Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mind Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mind Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.